Slingshot members are tracking this event:
Immunomedics (IMMU) to Complete Phase 3 Pivotal Trial Preparation for IMMU-132 in Metastatic Triple-Negative Breast Cancer in 2H 2016
Slingshot Insights Explained
Jan 18, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3 Pivotal Trial, Trial Preparation, Immu-132, Metastatic Triple-negative Breast Cancer, 2h 2016